‘Total artificial heart’: European Union set to approve temporary replacement hearts that are working, in 19-patient study

Credit: Carmat
Credit: Carmat

To help people awaiting a transplant, French company Carmat has developed a “total artificial heart” — a device to replace the whole heart until a donor can be found.

Similar in shape to a human heart and weighing 4 kilograms, it is powered by two battery packs that provide around four hours of charge before the device needs to be connected to a mains power supply.

“It works like a human heart so if the patient walks, the blood flow increases and if the patient is at rest, the blood flow is stable and low,” Carmat CEO Stéphane Piat tells CNN Business.


The parts in contact with the patient’s blood are made from material that’s compatible with the human body, to reduce the risk of adverse reactions. Once surgically implanted, the device requires no maintenance, says Piat.

Nineteen patients have so far received the device in trials and in December, the company received a CE marking, allowing Carmat to sell the product in the European Union. Last month, it received authorization to start a feasibility study to gain approval from the US Food and Drug Administration.

Follow the latest news and policy debates on agricultural biotech and biomedicine? Subscribe to our newsletter.

By the end of the year, Piat aims for Carmat to have made 20 hearts, which will be sold to hospitals for over €160,000 each ($190,000). 


Read the original post

Related article:  Cancer will be the ‘single biggest barrier to increasing our life expectancy,’ report says
Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Deaths from COVID-19 are far higher than reported estimates

Infographic: Deaths from COVID-19 are far higher than reported estimates

More than 2.8 million people have lost their lives due to the pandemic, according to a Wall Street Journal analysis ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend